Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response

Abstract excerpt

Background: Approximately 15%–20% of all diagnosed breast cancers are characterized by amplified and overexpressed HER2 (= ErbB2). These breast cancers are aggressive and have a poor prognosis. Although improvements in treatment have been achieved after the introduction of trastuzumab and lapatinib, many patients do not benefit from these drugs. Therefore, in-depth understanding of the mechanisms behind the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Treatment and Pharmacology
• Share to HER2/EGFR in Cancer Research
• Share to Protein Kinase Regulation and GTPase Signaling